Comparisons on Efficacy of Elcatonin and Limaprost Alfadex in Patients with Lumbar Spinal Stenosis and Concurrent Osteoporosis: A Preliminary Study Using a Crossover Design.
- Author:
Tsukasa KANCHIKU
1
;
Yasuaki IMAJO
;
Hidenori SUZUKI
;
Yuichiro YOSHIDA
;
Toshihiko TAGUCHI
;
Toshikatsu TOMINAGA
;
Koichiro TOYODA
Author Information
- Publication Type:Multicenter Study ; Original Article
- Keywords: Lumbar spinal stenosis; Osteoporosis; Pharmacotherapy; Limaprost alfadex; Elcatonin
- MeSH: Aging; Asian Continental Ancestry Group; Back Pain; Cross-Over Studies*; Drug Therapy; Health Surveys; Humans; Hypesthesia; Nociceptive Pain; Osteoporosis*; Prospective Studies; Quality of Life; Spinal Stenosis*; Walking; Surveys and Questionnaires
- From:Asian Spine Journal 2014;8(4):469-475
- CountryRepublic of Korea
- Language:English
- Abstract: STUDY DESIGN: Multicenter prospective study with a crossover design. PURPOSE: The objective of this study is to compare the efficacy of limaprost alfadex (LP) and elcatonin (EL) for lumbar spinal stenosis (LSS) patients with concurrent osteoporosis. OVERVIEW OF LITERATURE: It has been increasingly important to improve quality of life by establishing appropriate conservative treatments for LSS patients with concurrent osteoporosis who will presumably continue to increase due to the percentage of the aging elevations, however there is no prospective study. METHODS: A total of 19 patients with LSS and concurrent osteoporosis were enrolled in this study. The patients were divided into two groups and compared using a crossover design. The Japanese Orthopaedic Association Back Pain Evaluation Questionnaire (JOABPEQ) and short-form (SF)-8 health survey scale were used for clinical evaluations. RESULTS: There was a significant improvement of buttock-leg pain and numbness in the EL group. A significant improvement of impaired walking function was noted for the LP group according to the JOABPEQ while the rest of the items in the JOABPEQ showed no significant differences. The SF-8 health survey revealed that somatic pains and physical summary scores in the EL group and physical functioning and physical summary scores in the LP group tended to improve but not to any statistically significant extents. CONCLUSIONS: Concomitant uses of EL may be useful in patients who do not respond satisfactorily to the treatments of LP for 6-8 weeks.
